Out with the old, in with the new: Decoding biosimilar access with VPAG
As the UK pharmaceutical sector adopts the VPAG scheme, the question of how this will impact biosimilars comes to the forefront.
As the UK pharmaceutical sector adopts the VPAG scheme, the question of how this will impact biosimilars comes to the forefront.
What's Your Reaction?
